by Kirsten Chalmers | Nov 24, 2021 | Budget impact, Market access
What is a budget impact analysis? Pressure on healthcare insurers to fund the best available care while keeping within budgetary constraints has made budget impact analysis (BIA) an increasingly important part of any application for getting new drugs or medical...
by Sam Bryning | Oct 6, 2021 | Cost-effectiveness analysis, Market access
Sam Bryning, intern at Symmetron: ‘formally accounting for structural uncertainty in cost-effectiveness models makes research and decision making more robust’. Cost-effectiveness models in healthcare attempt to capture the main features of clinical...
by Frank Grimsey Jones | Aug 21, 2021 | Health economic modelling, Market access
Health economic modelling is a process for synthesising and comparing the costs and benefits of new (proposed) and existing medicines or devices in order to make decisions about which interventions may lead to the best patient outcomes. It is a key component of the...
by Kristen Markus | Aug 13, 2021 | Clinical trial, Evidence generation, Health outcomes, Market access, Medical affairs
Clinical evidence generation: clinical trials Health researchers continually discover new evidence that deepens our understanding of disease processes and progression. This rapidly evolving knowledge must be integrated into ongoing research and development of new...
by Kristen Markus | Aug 13, 2021 | Evidence synthesis, Health outcomes, Healthcare, Market access
What is evidence synthesis? As the pharmaceutical market rapidly evolves to keep pace with patient needs and emerging research, healthcare decision makers must continuously re-evaluate the evidence base that informs their thinking. But how can they take into account...
by Anna Pagotto | Jul 6, 2021 | Market access, NICE, Oncology
The rapid development of immuno-oncology (I-O) therapies has transformed the cancer treatment landscape, but health technology assessment (HTA) agencies can decide against covering or reimbursing such treatments because of their complexity and high cost. As experts in...
